StageZero Life Sciences Ltd. (SZLSF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 1.78 Million USD | 584.23% |
| 2021 | -368.5 Thousand USD | 87.83% |
| 2020 | -3.02 Million USD | -226.73% |
| 2019 | 2.38 Million USD | -23.41% |
| 2018 | 3.11 Million USD | 102.11% |
| 2017 | 1.54 Million USD | -45.08% |
| 2016 | 2.8 Million USD | 248.63% |
| 2015 | 805.78 Thousand USD | 134.48% |
| 2014 | -2.33 Million USD | 7.01% |
| 2013 | -2.51 Million USD | 27.9% |
| 2012 | -3.48 Million USD | -209.32% |
| 2011 | 3.18 Million USD | -3.52% |
| 2010 | 3.3 Million USD | 45.93% |
| 2009 | 2.26 Million USD | 362.32% |
| 2008 | 489.86 Thousand USD | 105.38% |
| 2007 | -9.09 Million USD | 48.24% |
| 2006 | -17.57 Million USD | -359.96% |
| 2005 | -3.82 Million USD | 23.63% |
| 2004 | -5 Million USD | -153.07% |
| 2003 | -1.97 Million USD | -281.26% |
| 2002 | -518.67 Thousand USD | 47.86% |
| 2001 | -994.82 Thousand USD | 71.23% |
| 2000 | -3.45 Million USD | -12083.58% |
| 1999 | -28.37 Thousand USD | 70.63% |
| 1998 | -96.61 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.84 Million USD | 19.9% |
| 2024 Q1 | 1.71 Million USD | 0.0% |
| 2023 Q1 | 1.97 Million USD | 10.59% |
| 2023 Q2 | 1.41 Million USD | -28.16% |
| 2023 Q3 | 1.33 Million USD | -5.86% |
| 2022 Q2 | 1.29 Million USD | 86.31% |
| 2022 Q1 | 694.42 Thousand USD | 288.45% |
| 2022 FY | 1.78 Million USD | 584.23% |
| 2022 Q4 | 1.78 Million USD | 4.82% |
| 2022 Q3 | 1.7 Million USD | 31.58% |
| 2021 FY | -368.5 Thousand USD | 87.83% |
| 2021 Q4 | -368.5 Thousand USD | -99.31% |
| 2021 Q3 | -184.88 Thousand USD | 93.05% |
| 2021 Q2 | -2.66 Million USD | 40.85% |
| 2021 Q1 | -4.49 Million USD | -48.67% |
| 2020 Q4 | -3.02 Million USD | -288.89% |
| 2020 FY | -3.02 Million USD | -226.73% |
| 2020 Q1 | 2.53 Million USD | 5.96% |
| 2020 Q2 | -410.19 Thousand USD | -116.21% |
| 2020 Q3 | 1.6 Million USD | 490.65% |
| 2019 Q4 | 2.38 Million USD | -14.98% |
| 2019 Q2 | 2.99 Million USD | -27.34% |
| 2019 Q1 | 4.12 Million USD | 32.19% |
| 2019 Q3 | 2.8 Million USD | -6.2% |
| 2019 FY | 2.38 Million USD | -23.41% |
| 2018 Q4 | 3.11 Million USD | -13.09% |
| 2018 FY | 3.11 Million USD | 102.11% |
| 2018 Q1 | 2.08 Million USD | 34.83% |
| 2018 Q2 | 2.84 Million USD | 36.61% |
| 2018 Q3 | 3.58 Million USD | 26.26% |
| 2017 Q4 | 1.54 Million USD | -56.99% |
| 2017 Q3 | 3.58 Million USD | 6.22% |
| 2017 FY | 1.54 Million USD | -45.08% |
| 2017 Q1 | 3.05 Million USD | 8.74% |
| 2017 Q2 | 3.37 Million USD | 10.57% |
| 2016 Q1 | 2.02 Million USD | 151.47% |
| 2016 FY | 2.8 Million USD | 248.63% |
| 2016 Q4 | 2.8 Million USD | 26.62% |
| 2016 Q3 | 2.21 Million USD | -18.08% |
| 2016 Q2 | 2.7 Million USD | 33.65% |
| 2015 FY | 805.78 Thousand USD | 134.48% |
| 2015 Q4 | 805.78 Thousand USD | 66.31% |
| 2015 Q1 | -2.63 Million USD | -12.69% |
| 2015 Q2 | 443.1 Thousand USD | 116.83% |
| 2015 Q3 | 484.5 Thousand USD | 9.34% |
| 2014 Q2 | -511.68 Thousand USD | 55.19% |
| 2014 FY | -2.33 Million USD | 7.01% |
| 2014 Q1 | -1.14 Million USD | 54.57% |
| 2014 Q4 | -2.33 Million USD | 40.84% |
| 2014 Q3 | -3.95 Million USD | -671.98% |
| 2013 FY | -2.51 Million USD | 27.9% |
| 2013 Q3 | 4.09 Million USD | 2.81% |
| 2013 Q1 | 4.09 Million USD | 217.42% |
| 2013 Q2 | 3.97 Million USD | -2.77% |
| 2013 Q4 | -2.51 Million USD | -161.43% |
| 2012 Q2 | 3.43 Million USD | 13.52% |
| 2012 Q3 | 3.79 Million USD | 10.59% |
| 2012 Q1 | 3.02 Million USD | -5.21% |
| 2012 Q4 | -3.48 Million USD | -191.86% |
| 2012 FY | -3.48 Million USD | -209.32% |
| 2011 FY | 3.18 Million USD | -3.52% |
| 2011 Q4 | 3.18 Million USD | 17.13% |
| 2011 Q1 | 3.63 Million USD | 9.98% |
| 2011 Q2 | 2.64 Million USD | -27.12% |
| 2011 Q3 | 2.72 Million USD | 2.77% |
| 2010 Q4 | 3.3 Million USD | 23.61% |
| 2010 FY | 3.3 Million USD | 45.93% |
| 2010 Q1 | 2.18 Million USD | -3.42% |
| 2010 Q2 | 2.77 Million USD | 26.94% |
| 2010 Q3 | 2.67 Million USD | -3.7% |
| 2009 Q2 | 1.96 Million USD | 24.07% |
| 2009 Q3 | 1.38 Million USD | -29.63% |
| 2009 FY | 2.26 Million USD | 362.32% |
| 2009 Q1 | 1.58 Million USD | 223.04% |
| 2009 Q4 | 2.26 Million USD | 63.92% |
| 2008 Q4 | 489.86 Thousand USD | 135.38% |
| 2008 FY | 489.86 Thousand USD | 105.38% |
| 2008 Q1 | -7.18 Million USD | 21.07% |
| 2008 Q2 | -5.02 Million USD | 30.09% |
| 2008 Q3 | -1.38 Million USD | 72.42% |
| 2007 Q3 | -16.64 Million USD | -7.22% |
| 2007 Q4 | -9.09 Million USD | 45.33% |
| 2007 FY | -9.09 Million USD | 48.24% |
| 2007 Q1 | -16.54 Million USD | 5.89% |
| 2007 Q2 | -15.52 Million USD | 6.18% |
| 2006 FY | -17.57 Million USD | -359.96% |
| 2006 Q1 | -3.63 Million USD | 5.01% |
| 2006 Q2 | -23.01 Million USD | -533.82% |
| 2006 Q3 | -20.84 Million USD | 9.41% |
| 2006 Q4 | -17.57 Million USD | 15.67% |
| 2005 Q2 | -6.65 Million USD | 13.4% |
| 2005 Q3 | -5.51 Million USD | 17.18% |
| 2005 Q4 | -3.82 Million USD | 30.64% |
| 2005 FY | -3.82 Million USD | 23.63% |
| 2005 Q1 | -7.68 Million USD | -53.51% |
| 2004 Q1 | -2.09 Million USD | -5.95% |
| 2004 Q3 | -5.48 Million USD | -433.83% |
| 2004 Q4 | -5 Million USD | 8.8% |
| 2004 FY | -5 Million USD | -153.07% |
| 2004 Q2 | -1.02 Million USD | 50.94% |
| 2003 FY | -1.97 Million USD | -281.26% |
| 2003 Q4 | -1.97 Million USD | 16.22% |
| 2003 Q3 | -2.36 Million USD | 19.94% |
| 2003 Q2 | -2.94 Million USD | -78.95% |
| 2003 Q1 | -1.64 Million USD | -132.43% |
| 2002 Q1 | -827.23 Thousand USD | -100.2% |
| 2002 Q3 | -566.34 Thousand USD | 48.66% |
| 2002 Q4 | -708.83 Thousand USD | -25.16% |
| 2002 FY | -518.67 Thousand USD | 47.86% |
| 2002 Q2 | -1.1 Million USD | -33.35% |
| 2001 Q3 | -819.55 Thousand USD | 17.62% |
| 2001 Q4 | -413.19 Thousand USD | 49.58% |
| 2001 Q1 | -1.48 Million USD | 32.17% |
| 2001 FY | -994.82 Thousand USD | 71.23% |
| 2001 Q2 | -994.82 Thousand USD | 33.11% |
| 2000 Q3 | -2.62 Million USD | 0.0% |
| 2000 FY | -3.45 Million USD | -12083.58% |
| 2000 Q1 | -42.67 Thousand USD | -50.38% |
| 2000 Q4 | -2.19 Million USD | 16.37% |
| 1999 Q1 | -91.39 Thousand USD | 0.0% |
| 1999 FY | -28.37 Thousand USD | 70.63% |
| 1999 Q2 | -83.51 Thousand USD | 8.61% |
| 1999 Q3 | -37.91 Thousand USD | 54.61% |
| 1999 Q4 | -28.37 Thousand USD | 25.15% |
| 1998 FY | -96.61 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | 19.112% |
| Arrayit Corporation | 1.05 Million USD | -69.044% |
| Atlantic International Corp. | 236.49 Thousand USD | -654.516% |
| Biocept, Inc. | -788 Thousand USD | 326.447% |
| Bioqual, Inc. | -12 Million USD | 114.861% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | -7747.306% |
| DermTech, Inc. | 17.65 Million USD | 89.892% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 100.312% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 124.189% |
| iMD Companies, Inc. | 1.11 Million USD | -59.905% |
| IDenta Corp. | 524.85 Thousand USD | -239.981% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 76.808% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | 6720.655% |
| InVitro International | -313.14 Thousand USD | 669.837% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | -13.953% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | 250366.339% |
| Medical Imaging Corp. | 3.79 Million USD | 52.93% |
| NovelStem International Corp. | 3.52 Million USD | 49.329% |
| Optigenex Inc. | 8.93 Million USD | 80.027% |
| PharmChem, Inc. | -1.49 Million USD | 219.405% |
| Proteome Sciences plc | 14.57 Million USD | 87.756% |
| Response Genetics, Inc | -13.08 Million USD | 113.636% |
| Rennova Health, Inc. | 14.82 Million USD | 87.968% |
| RushNet, Inc. | 4.8 Million USD | 62.832% |
| ScreenPro Security Inc. | 135.58 Thousand USD | -1216.035% |
| Stella Diagnostics Inc. | 6.19 Million USD | 71.187% |
| Todos Medical Ltd. | 38.31 Million USD | 95.343% |